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Abstract
Compared to normal differentiated cells, cancer cells have altered metabolic regulation to support
biosynthesis and the expression of the M2 isozyme of pyruvate kinase (PKM2) plays an important
role in this anabolic metabolism. While the M1 isoform is a highly active enzyme, the
alternatively spliced M2 variant is considerably less active and expressed in tumors. While the
exact mechanism by which decreased pyruvate kinase activity contributes to anabolic metabolism
remains unclear, it is hypothesized that activation of PKM2 to levels seen with PKM1 may
promote a metabolic program that is not conducive to cell proliferation. Here we report the third
chemotype in a series of PKM2 activators based on the 2-oxo-N-aryl-1,2,3,4-
tetrahydroquinoline-6-sulfonamide scaffold. The synthesis, structure activity relationships,
selectivity and notable physiochemical properties are described.
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The M2 isoform of pyruvate kinase (PKM2) is expressed in tumor cells and has been
proposed as a diagnostic marker for a large number of cancers[1]. While the expression of
this isoform in tumors has been known for a number of years[2], recent work [3–5] has
invigorated considerable interest in understanding pyruvate kinase regulation and the
possibility of targeting PKM2 for cancer therapy [6–8]. One study has shown that the
aberrant metabolism of cancer cells and their production of high levels of lactate in aerobic
conditions could be reversed by replacement of the M2 isoform of pyruvate kinase (PK)
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with the M1 isoform [3]. Rescue of cells subjected to shRNA knock-down of PKM2 with
PKM1 also showed reduced tumor formation in a xenograft model. Pyruvate kinase
functions in glycolysis to catalyze conversion of phosphoenolpyruvate (PEP) to pyruvate
with concomitant generation of ATP from ADP. There are four mammalian PK isoforms
encoded by two genes located on two distinct chromosomes [9–13]. Encoded by PKLR,
PKR is found in erythrocytes and PKL is expressed in both the liver and kidney. The PKM
gene also has two splice varients; PKM1 that is predominantly found in muscle and brain
tissue and PKM2 that is expressed in some adult tissues, embryonic tissues and tumor cells
[1]. Regardless of the isoform, the active form of PK is a tetramer. PKM2, PKL and PKR
are allosterically activated in a feed forward mechanism by fructose-1,6-bisphosphate (FBP)
while PKM1, which is expressed in tissues with high ATP requirements, does not require
allosteric activation [14]. While it has been reported that PKM2 in tumors exists
predominantly as an inactive dimer [1,15], exactly how this contributes to tumorigenesis and
the Warburg effect is still unknown.
It has been hypothesized that cancer cells benefit from the low activity of PKM2 to increase
levels of glycolytic intermediates for use in anabolic processes including nucleic acid, amino
acid, and lipid syntheses [15]. This suggests that pharmacological activation of PKM2 to
levels associated with PKM1 may inhibit cell proliferation as well as be a potential
therapeutic strategy for cancer. Our group has previously reported two chemotypes capable
of activating PKM2 including a series of diarylsulfonamides [16] and a series of thieno[3,2-
b]pyrrole[3,2-d]pyridazinones [17] (exemplified by 1 and 2 respectively in Figure 1). Here,
we describe the development of a series of PKM2 activators derived from the 2-oxo-N-aryl-
tetrahydroquinoline-6-sulfonamide lead, 3.
Using our previously described qHTS assay for PKM2 activators [16], compound 3 was
found to have an AC50 = 790 nM in the primary screen. Resynthesis of the hit as well as the
majority of analogs described in Tables 1 and 2 was accomplished via base-mediated
coupling of commercially available anilines and sulfonyl chlorides in DMF, as represented
in Scheme 1. An array of commercially available anilines were coupled with sulfonyl
chlorides using either Hunig’s base or pyridine in DMF solvent.
We began by looking at potential modification of the aryl linkage, but the importance of the
NH-sulfonamide was apparent after both the N-methylsulfonamide and amide-linked
derivatives showed a complete loss in activity (data not shown). We next investigated the
importance of the 3,4-dihydroquinolin-2(1H)-one moiety by removing of the amide
functionality to generate a number of simple substituted benzene derivates (5 – 9). While a
number of these retained activity, they all showed significantly diminished potency (≥ 20-
fold) and/or efficacy. Informed by these results, we next investigated various amide, urea
and carbamate derivatives as well as heteroatom inclusion. A few interesting SAR points
from these modifications were: placing the amide carbonyl outside of the ring (14 and 22),
changing the amide ring structure to a 5- or 7-membered rings (15 and 16) or removing the
cyclic nature of the amide (13 and 17), all resulted in a significant loss of potency. In
general, most analogs that altered the 6-membered lactam moiety saw a considerable drop in
activity.
The next SAR we wanted to explore was altering the 3,4-dimethylaniline moiety by addition
of a variety of substituted anilines to the commercially available 2-oxo-1,2,3,4-
tetrahydroquinoline-6-sulfonyl chloride (Table 2). Preference for substitution of
hydrophobic groups at the meta-position quickly emerged as a key for potency as the 3-
methyl (24), 3-fluoro (27) and 3-chloro (29) analogs all had AC50 values <800 nM. Notably,
the 3-methoxy analog (34) saw a potency drop of >4-fold compared to the 3-methyl version.
All ortho-substituents tested resulted in a marked decrease in activity while more tolerance
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was observed at the para-position. Noteworthy inactive analogs were pyridine derivatives
31 and 32 as well as the quinoline derivative (39) for which the non-nitrogenous 2-
naphthalene analog (38) had reasonable activity (1.3 μM). Tethering the hydrophobic
dimethyl group in a dihydroindene ring resulted in a much less potent analog (40), while
combinations of methyl, fluoro and chloro at the 3- and 4-positions resulted in a number of
analogs with good potencies (41 – 46). Both the 3-chloro-4-methyl (41) and 3-chloro-4-
fluoro (45) derivatives had potencies <300 nM, so these, along with the original 3,4-
dimethyl substitution patterns were chosen as motifs to carry on.
Derivatives with various substituents at the 6-position of 3,4-dihydroquinolin-2(1H)-one-7-
sulfonamides, the 7-position of 3,4-dihydroquinolin-2(1H)-one-6-sulfonamides, and the 6-
position of 3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-sulfonamides were examined next
(Table 3). 6-bromo-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-sulfonyl chloride was
coupled with 3,4-dimethylaniline and then subjected to standard Suzuki cross coupling
conditions to provide a variety of aryl substituted dihydro-2H-benzo[b][1,4]oxazines
(Scheme 2A). Generally, the addition of aryl and heteroaryl substituents resulted in
decreased reactivity (exemplified by 47 and 48 in Table 3).
Good activity was obtained starting with 7-fluoro-2-oxo-1,2,3,4-tetrahydroquinoline-6-
sulfonyl chloride to generate 51 with a potency of 210 nM. This particular analog was
further modified by introduction of nitrogen nucleophiles through SNAr reactions in
acetonitrile (Scheme 2B). Significant SAR was seen with substitution of a variety of these
analogs. Sterically larger groups like N,N-dimethylpyrrolidin-3-amine (56) and piperidine
(57) resulted loss of activity while smaller dimethyl- (52) and methyl-amine (54) derivatives
retained activity. With the realization that small amines were tolerated at this position a few
analogs were generated in an effort to improve both solubility and potency (58 – 63). The
racemic alaninol derivative provided high aqueous kinetic solubility (>120 μM in PBS
buffer) while retaining low nanomolar potency (61). Preparation of the enantiopure versions
with (S)- and (R)-alaninol resulted the (S)-derivative being 4-fold more potent than its
enantiomer (880 nM for 62 vs 170 nM for 63). Combination of 7-fluoro or 7-(S)-alaninol
derivatives with the best aniline analogs from Table 2 gave compounds 64 – 70, which all
have low nanomolar activity with good maximum response. Interestingly, it was discovered
that flipping the amide orientation to generate the 6-chloro- and 6-(dimethylamino)-3,4-
dihydroquinolin-2(1H)-one-7-sulfonamide derivatives gave potent analogs 71 – 73. These
results led us to develop chemistry to quickly access these constitutional isomers (Scheme
3). The sulfonylation of 78 generated regioisomers that after coupling with 79 afforded 74a
and 74b or with aniline 80 afforded 75a and 75b. Analogs 74a and 75a had weak activity
(>5μM) while their regioisomers, 74b and 75b had no activity (data not shown). The
incorporation of the (S)-alaninol through Ullmann chemistry for the active bromide isomers
generated 76a and 77a, but rather surprisingly, these compounds had significantly
diminished activity compared to analogs 63 and 68 respectively. Buchwald chemistry was
required for the conversion of 74b and 75b to the alaninol-substituted derivatives 76b and
77b, respectively. Both of these analogs proved to be inactive, as well (data not shown).
Having generated a number of analogs with potencies <200 nM, a select few were taken on
to assess their selectivity against the other PK isoforms (Figure 2). All analogs tested had no
activity against the R or M1 isoforms and showed only minimal activation of the L isoform
(≤25% at 57.5 μM). Compound 66 was also tested for its ability to modulate PEP and ADP
affinity for hPKM2 (Figure 3). As with our previously reported activators [16,17], this
analog showed significant decrease in Km for PEP (Km ~ 1.9 mM without 66, 0.4 mM with
66) while not affecting the Km of ADP (Km ~ 0.1 mM in both conditions). A number of
analogs were also taken on to test their cell permeability and in vitro microsomal stability in
both mouse and human liver microsomes (Caco-2, MLM and HLM in Table 4). While the
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original lead (3) had moderate Caco-2 permeability with an efflux ratio <1, it had poor
microsomal stability in both mouse and human liver microsomes (t1/2<20 minutes). It
became apparent that while the alaninol substituent provided good solubility and potency,
high efflux ratios and reduced MLM half lives were attributable to the incorporation of this
side-chain (68 and 69 in Table 4). A more drastic reduction in microsomal stability was seen
with the N-methyl- and N,N-dimethyl-derivatives 52 and 54 both having half lives <25
minutes. This data suggests that alkyl-amine substitution at this position engenders the
molecules with efflux and/or microsomal stability liabilities. Compounds showing good
permeability and efflux ratios (≤1) had either hydrogen or fluorine substituents at the 7-
position (3, 64 and 66). The metabolic liabilities of the meta- and para-groups was assessed
by comparing analogs 51, 64 and 66. Switching the meta-methyl group to a meta-chlorine
slightly decreased both human and mouse microsomal stability (compare 64 to 51). Further,
switching the para-methyl group on 64 to a para-fluorine on 66 saw a marked increase in
both HLM and MLM with a half life of 277.2 and 117.5 minutes respectively.
In conclusion, we have developed a third novel chemotype capable of activating PKM2.
These molecules, based on the 2-oxo-N-aryl-1,2,3,4-tetrahydroquinoline-6-sulfonamide
scaffold, have low nanomolar potency with a notable analog, 66, having an AC50 of 90 nM
with selectivity over other PK isoforms, good Caco-2 permeability, a low efflux ratio (0.84)
and high microsomal stability (t1/2 = 277.2 min in HLM and 117.5 min in MLM).
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Figure 1.
Chemical Structures of Previously Reported hPKM2 Activators NCGC00185916 (1),
NCGC00186527 (2) and qHTS Hit NCGC00185939 (3).
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Figure 2.
Pyruvate Kinase Isoform Selectivity Profile.
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Figure 3.
Compound 66 affects PEP affinity, but not ADP affinity. (A) Initial velocity as a function of
ADP concentration in the absence (○) or presence (●) of 66 (10 μM). (B) Initial velocity as a
function PEP concentration in the absence (○) or presence (●) of 66 (10 μM). Vo, initial rate
in pmol/min as determined in the PK-LDH coupled assay (kinetic assays were carried out at
approximately 22 °C with 10 nM PKM2 using [KCl] = 200 mM, [MgCl2] = 15 mM, and
with either [ADP] or [PEP] = 4.0 mM; see Supporting Information).
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Scheme 1.
General Synthetic Methodology Used to Access Analogs in Tables 1 and 2.
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Scheme 2.
General Synthetic Methodology Used to Access Analogs in Table 3.
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Scheme 3.
Synthesis of 6-Substituted 3,4-Dihydroquinolin-2(1H)-one-7-sulfonamides
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Table 1
SAR of N-(3,4-Dimethylphenyl)arylsulfonamides
# R hPK M2 AC50 (μM)a hPK M2 max resp. (%)b
4 5-(N-methylindole) 19.9 47
5 3-(benzoic acid) >20 NA
6 4-fluoro-C6H4 >20 NA
7 2-napthalene 18.4 69
8 3-chloro-C6H4 18.3 71
9 4-methoxy-C6H4 17.3 53
10 6-(2,2-dimethylchroman) 10.0 62
11 6-(2H-benzo[b][1,4]oxazin-3(4H)-one) 13.4 81
12 5-(1H-benzo[d]imidazol-2(3H)-one) >20 NA
13 3-NHAcetyl-C6H4 13.1 58
14 6-(N-acetyl-tetrahydroquinoline) 9.0 76
15 5-(indolin-2-one) 8.3 57
16 7-(4,5-dihydro-1H-benzo[b]azepin-2(3H)-one) 7.1 88
17 4-NHAcetyl-C6H4 6.9 <40
18 6-(3-methylbenzo[d]oxazol-2(3H)-one) 4.3 95
19 6-(4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine) 6.0 81
20 4-(2-oxopyrrolidin-1-yl)-C6H4 0.94 60
21 5-(1-methylindolin-2-one) 2.3 119
22 5-(N-acetyllindoline) 1.5 96
a
AC50 values were determined utilizing the luminescent pyruvate kinase-luciferase coupled assay (ref. 16) and the data represents the average
from three separate experiments. Max Res. (Maximum Response) is % activity that represents the % activation at 57 μM of compound. See
supporting information for normalization.
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Table 2
SAR of 2-Oxo-1,2,3,4-tetrahydroquinoline-6-sulfonamides
# R hPK M2 AC50 (μM)a hPK M2 Max Resp. (%)b
23 2-methyl-benzene 2.2 94
24 3-methyl-benzene 0.25 101
25 4-methyl-benzene 1.4 102
26 2-fluoro-benzene 5.2 95
27 3-fluoro-benzene 0.79 101
28 4-fluoro-benzene 6.0 84
29 3-chloro-benzene 0.41 104
30 4-chloro-benzene 2.0 106
31 4-(pyridine) >20 NA
32 3-(pyridine) >20 NA
33 4-methoxy-benzene 16.3 85
34 3-methoxy-benzene 1.1 115
35 3-phenyl-benzene >20 NA
36 6-(2,3-dihydrobenzo[b][1,4]dioxine) 11.1 100
37 3-trifluoromethyl-benzene 6.4 109
38 2-napthalene 1.3 121
39 6-(quinoline) >20 NA
40 5-(2,3-dihydro-1H-indene) 4.6 73
41 3-chloro-4-methyl-benzene 0.10 104
42 3,4-dichloro-benzene 1.3 95
43 4-chloro-3-methyl-benzene 0.56 121
44 3-fluoro-4-methylbenzene 0.54 138
45 3-chloro-4-fluoro-benzene 0.29 123
46 4-fluoro-3-methyl-benzene 0.44 128
a
AC50 values were determined utilizing the luminescent pyruvate kinase-luciferase coupled assay (ref. 16) and the data represents the average
from three separate experiments. Max Res. (Maximum Response) is % activity that represents the % activation at 57 μM of compound. See
supporting information for normalization.
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